FLT3 and acute myeloid leukemia: LSD1 and DOT1L therapies exemplify a broader AML treatment principle: rewriting the chromatin state to unlock lineage maturation, then pairing with BH3 mimetics (e.g., venetoclax) or kinase inhibitors (e.g., FLT3 inhibitors) to convert differentiation into durable disease clearance.